Johnson & Johnson Stock Surges as Pharma Growth Revives Investor Confidence

Johnson & Johnson (JNJ) is a global healthcare giant with operations spanning prescription medicines and medical technology. The company has a market cap of $640.5 billion, making it one of the largest in the industry.

JNJ's recent performance has been strong, with the stock up 16.1% over the past three months, outperforming the State Street Consumer Staples Select Sector SPDR Fund (XLP), which climbed 1.2%. Over the past 52 weeks, JNJ has surged 52.8%, outpacing XLP's 6.5% rise.

The stock is also trading above its 50-day and 200-day moving averages for most of the past year, indicating an uptrend. Johnson & Johnson released its FY2026 Q2 earnings on July 15, with shares rising 1.2% in the next trading session.